Table 3 Drugs for AMPs in clinical phase III

p2TA(AB103, Reltecimod)

Reltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections)

Necrotizing soft tissue infections

Atox Bio Ltd

Ramoplanin(NTI-851)

Ramoplanin (NTI-851) is a macrocyclic glycolipodepsi peptide produced by Actinoplanes spp. being developed by Nano-therapeutics. It exhibits bactericidal activity by blocking the cell wall peptidoglycan synthesis of gram-positive bacteria. Recently, the phase III clinical study of the peptide was initiated for the oral treatment of vancomycin-resistantenterococcus (VRE) colonization, as well as the phase II trial against Clostridium difficile

Treatment of bacterial infections

Nano-therapeutics

XMP 629(HY-P2170; CS-0109623)

Extracted from human

Impetigo and acne rosacea

Xoma Ltd(Berkeley, CA, USA)

Mycoprex

Extracted from insects

Fungal infections

Xoma Ltd

Talactoferrin alpha (Lactoferroxin-A)

Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation

Combined with chemotherapy in the first-line treatment of advanced non-small cell lung cancer; Topical treatment in diabetic neutropathic ulcers

Agennix

D2A21 (Demegal, Provena)

A 22-residue αhelix peptide

Burn infection, skin infection with multidrug-resistant pathogens

Demegen

Glutoxim (NOV-002)

Glutathione Disulfide NOV-002 is a stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and immunomodulating activities

Tuberculosis, non small cell, lung cancer

Pharma BAM/Novelos

XOMA-629

9-amino-acid peptide derivative of bactericidal/permeability-increasing protein

Impetigo

Xoma

DiaPep277

DiaPep277 is a small, lyophilized powder containing 24 Amino-acids. It has proved in former studies that DiaPep277 can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes

Type 1 diabetes mellitus

DeveloGen

Dusquetide(SGX942)

Dusquetide is a synthetic, 5-amino acid peptide and Innate Defense Regulator (IDR), with immunomodulating, anti-inflammatory, anti-infective and anti-mucositis activities

Treatment for oral complications caused by radiation therapy for head and neck cancer

Soligenix

Omiganan (MBI-226/MX-226/CLS001)

Omiganan (MBI-226), an analogue of indolicidin, has been proven to be capable of significantly reducing catheter colonization and microbiologically confirmed tunnel infections during catheterization

Rosacea, Acne vulgaris (II), Genital warts (II)

Maruho Co., Ltd(developing), Cutanea Life Sciences, Inc. (developing), Mallinckrodt, Micrologix Biotech(Vancouver, BC, Canada)

PL-5

This product is a national category 1 anti-infective innovation category in China, and has obtained PCT US and Chinese invention patent authorizations

Skin wound infection

Changchun ProteLight Pharmaceutical & Biotechnology Co

Surotomycin(MK-4261/CB-183,315)

Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections

Treatment of Diarrhea and Clostridium Difficile Infection

Cubist Pharmaceuticals Inc./Merck & Co. Inc

TD-1792(Cefilavancin)

Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria

Gram-positive infections, Skin and soft tissue infections

GlaxoSmithKline Co., Theravance Biopharma Inc., R-Pharm